Need Help?

A mechanistic classification of clinical phenotypes in neuroblastoma

Clinical courses of the pediatric tumor neuroblastoma range from fatal progression to spontaneous regression. To gain insights into the pathogenesis of these divergent subtypes, we performed massively parallel sequencing of 416 pretreatment neuroblastomas and assessed telomere maintenance mechanisms in 208/416 cases. We observed that telomere maintenance and mutations in RAS or p53 pathway genes strongly affected disease courses. Fatal outcome occurred only in the presence of telomere maintenance, whereas patients whose tumors lacked such mechanisms had excellent outcome. In patients with telomere maintenance-positive tumors, survival was dramatically inferior when additional RAS/p53 pathway mutations were present. By contrast, spontaneous regression occurred both in the presence and absence of RAS/p53 pathway mutations in patients with telomere maintenance-negative tumors. Together, our data provide a precise mechanistic classification of clinical neuroblastoma phenotypes based on telomere maintenance mechanisms and genetic alterations of the tumor.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004449 Illumina HiSeq 2500 unspecified 1054
EGAD00001004450 unspecified 324
Publications Citations
A mechanistic classification of clinical phenotypes in neuroblastoma.
Science 362: 2018 1165-1170
141
CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature.
Sci Rep 10: 2020 19316
4
Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.
J Pers Med 11: 2021 691
2
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.
Sci Adv 8: 2022 eabn1382
7
Genomic ALK alterations in primary and relapsed neuroblastoma.
Br J Cancer 128: 2023 1559-1571
5